<code id='97C163A176'></code><style id='97C163A176'></style>
    • <acronym id='97C163A176'></acronym>
      <center id='97C163A176'><center id='97C163A176'><tfoot id='97C163A176'></tfoot></center><abbr id='97C163A176'><dir id='97C163A176'><tfoot id='97C163A176'></tfoot><noframes id='97C163A176'>

    • <optgroup id='97C163A176'><strike id='97C163A176'><sup id='97C163A176'></sup></strike><code id='97C163A176'></code></optgroup>
        1. <b id='97C163A176'><label id='97C163A176'><select id='97C163A176'><dt id='97C163A176'><span id='97C163A176'></span></dt></select></label></b><u id='97C163A176'></u>
          <i id='97C163A176'><strike id='97C163A176'><tt id='97C163A176'><pre id='97C163A176'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:entertainment    Page View:7
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          Gain of function research would be limited under House proposal
          Gain of function research would be limited under House proposal

          Rep.ThomasMassie(R-Ky.)KevinDietsch/GettyImagesWASHINGTON—HouselawmakerslateTuesdayvotedtoattachaU.S

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          FDA's Woodcock to retire early next year

          PrincipalDeputyFDACommissionerJanetWoodcockStefaniReynolds/TheNewYorkTimesviaAPWASHINGTON—PrincipalD